Notifying FDA of a Discontinuance or Interruption in Manufacturing

Not directly mentioned Nitrosamines, but this should be on the radar for our regulatory affairs members…
FDA announced the availability draft guidance on

“Notifying FDA of a Discontinuance or Interruption in Manufacturing of Finished Products or Active Pharmaceutical Ingredients Under Section 506C of the FD&C Act”

2 Likes